Objective To construct a recombinant bacterial vaccine which can express specific 10-23 deoxyribozyme(DZ) in macrophage, identify the intracellular production of specific 10-23DZ and detect the activity of this recombinant bacterial vaccine on inhibiting the expression of TACO gene in macrophage.Methods The pSDE02 was obtained by inserting the replicon of Mycobacterium into pSDE01, a plasmid which can express 10-23DZ in eukaryotic cells. The expression sequence of DZ1, a 10-23DZ targeting the TACO mRNA of macrophage designed in our previous study was synthesized and inserted into pSDE02. The resulted plasmid was named pDZM01. pDZM01 was then transferred into Mycobacterium smegmatis by electroperation. The recombinant M. smegmatis, named rMs-DZ1 was screened on low-salt LB medium containing Zeocin and identified by Colony PCR. The targeted delivery property of recombinant M. smegmatis was observed by Ziehl-Heelson stain and GFP expression observation via fluorescence microscope. rMs-DZ1 was used to infect RAW264.7 cells and the expression of DZ1 in macrophage was identified by dot-blot assay. At 24 h and 48 h after infection, total RNA and proteins were extracted and the TACO mRNA and protein expression level was assayed by RT-PCR and western-blot respectively. Results Restrictive analysis and sequencing data showed that the Mycobacterium-eukaryotic cell shuttle plasmid pSDE02 and pDZM01 was successfully constructed. rMs-DZ1 was confirmed by colony PCR. When engulfed by macrophage, rMs-DZ1 would express DZ1 in RAW264.7 cells and inhibit the expression of taco gene. When compared to uninfected macrophage, rMs-DZ1 significantly reduced the taco mRNA by 67.90% and 57.14% and down-regulated the expression of TACO protein by 53.85% and 68.92% at 24 h and 48 h respectively. Conclusion A recombinant M. smegmatis vaccine was successfully constructed which could generate specific 10-23DZ in macrophage and inhibit the expression of target gene of interest. To our knowledge, this is the first bacterial vector which can express intracellularly 10-23DRz in targeted manner. This study may further prompt the feasibility of using 10-23 DNAzyme to achieve effective and targeted gene silence.

Objective:To explore the relationship between changes in levels of thrombomodulin (TM) and non high-density lipoprotein cholesterol (non-HDL-C) with ascending aortic elastic function and degree of coronary artery disease (CHD) in patients with coronary heart disease (CHD).Methods:A total of 147 patients with coronary heart disease diagnosed through coronary angiography at Yulin First Hospital from January 2018 to December 2022 were selected as the CHD group. In addition, 90 volunteers who underwent health examinations at our hospital and did not experience coronary artery disease were selected as the control group. Two groups were compared in terms of blood lipids [triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C)], ascending aortic elastic function parameters [arterial dilation (AD), arterial stiffness index (ASI)], TM, non HDL-C levels, and other indicators, and stratified analysis was conducted according to the number of coronary lesions. The linear correlation analysis method was used to analyze the relationship between TM, non-HDL-C, Gensini score, and ascending aortic elastic function parameters.Results:The serum levels of TG, TC, LDL-C, TM, and non HDL-C in the CHD group were significantly higher than those in the control group, while the HDL-C levels were lower than those in the control group, with statistical significance (all P<0.05). The ASI of the ascending aorta in the CHD group was significantly higher than that in the control group, while the AD was lower than that in the control group, and the differences were statistically significant (all P<0.05). The serum levels of TG, TC, LDL-C, TM, and non HDL-C in CHD patients with multiple coronary artery lesions were significantly higher than those in patients with dual or single coronary artery lesions, and the HDL-C levels were lower than those in patients with dual or single coronary artery lesions, with statistical significance (all P<0.05); The serum levels of TM and non HDL-C in CHD patients with dual coronary artery disease were significantly higher than those in single coronary artery disease patients, and the HDL-C levels were lower than those in single coronary artery disease patients, with statistical significance (all P<0.05). The ASI of CHD patients with multiple coronary artery lesions was significantly higher than that of patients with dual or single coronary artery lesions, and the AD was lower than that of patients with dual or single coronary artery lesions, with statistical significance (all P<0.05); The ASI of CHD patients with dual coronary artery disease was significantly higher than that of patients with single coronary artery disease, and the AD was lower than that of patients with single coronary artery disease, with statistical significance (all P<0.05). The TM, non HDL-C levels in CHD patients were significantly negatively correlated with AD (all P<0.05), and positively correlated with ASI and Gensini scores (all P<0.05). Conclusions:The levels of TM and non HDL-C in CHD patients significantly increase, and the ascending aortic elasticity function was decreased. TM and non HDL-C are related to coronary elasticity function and the severity of coronary artery disease.